Prestige Consumer Healthcare Inc. $PBH Holdings Lowered by New York State Teachers Retirement System

New York State Teachers Retirement System reduced its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 54.1% in the first quarter, HoldingsChannel reports. The fund owned 26,239 shares of the company’s stock after selling 30,951 shares during the quarter. New York State Teachers Retirement System’s holdings in Prestige Consumer Healthcare were worth $1,555,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the stock. UMB Bank n.a. raised its holdings in Prestige Consumer Healthcare by 110.1% during the fourth quarter. UMB Bank n.a. now owns 418 shares of the company’s stock worth $26,000 after purchasing an additional 219 shares in the last quarter. Bayforest Capital Ltd acquired a new position in shares of Prestige Consumer Healthcare during the 4th quarter valued at $29,000. Geneos Wealth Management Inc. increased its position in shares of Prestige Consumer Healthcare by 92.8% during the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock valued at $48,000 after purchasing an additional 269 shares during the period. Torren Management LLC bought a new stake in shares of Prestige Consumer Healthcare in the 4th quarter worth $35,000. Finally, Caitong International Asset Management Co. Ltd lifted its holdings in shares of Prestige Consumer Healthcare by 69.8% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 574 shares of the company’s stock valued at $35,000 after buying an additional 236 shares during the period. Institutional investors and hedge funds own 99.95% of the company’s stock.

Prestige Consumer Healthcare Price Performance

Shares of PBH traded up $0.44 during trading hours on Friday, hitting $48.92. 347,087 shares of the company were exchanged, compared to its average volume of 673,677. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.57 and a quick ratio of 2.25. The company has a market capitalization of $2.32 billion, a PE ratio of 12.51, a PEG ratio of 1.57 and a beta of 0.35. The firm has a fifty day simple moving average of $48.47 and a 200-day simple moving average of $57.82. Prestige Consumer Healthcare Inc. has a one year low of $42.62 and a one year high of $77.67.

Prestige Consumer Healthcare (NYSE:PBH) last announced its earnings results on Wednesday, May 13th. The company reported $1.23 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.39 by ($0.16). Prestige Consumer Healthcare had a return on equity of 11.54% and a net margin of 17.48%.The company had revenue of $281.62 million for the quarter, compared to analyst estimates of $293.64 million. During the same period last year, the firm earned $1.32 earnings per share. The firm’s revenue for the quarter was down 5.0% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. As a group, sell-side analysts predict that Prestige Consumer Healthcare Inc. will post 4.45 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts recently weighed in on PBH shares. Weiss Ratings cut Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, June 25th. Canaccord Genuity Group cut their price target on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a report on Friday, May 15th. Zacks Research lowered shares of Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research report on Monday, May 18th. Finally, Oppenheimer cut shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 14th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $70.75.

Insider Transactions at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 1,207 shares of the business’s stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $54.99, for a total transaction of $66,372.93. Following the sale, the vice president owned 42,820 shares in the company, valued at approximately $2,354,671.80. The trade was a 2.74% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.50% of the company’s stock.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).